The global PEGylated proteins market is anticipated to grow at a considerable CAGR of 1.8% during the forecast period 2023-2030). The rising FDA approvals to increase therapeutic application of PEGylated proteins is a key factor driving the growth of the global PEGylated proteins market. For instance, in December 2022, Protalix BioTherapeutics, Inc., a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx plant cell based protein expression system, and Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases, announced that the US Food and Drug Administration (FDA) has accepted the resubmitted Biologics License Application (BLA) for pegunigalsidase alfa (PRX-102) for the proposed treatment of adult patients with Fabry disease.
Browse the full report description of “PEGylated Proteins Market Size, Share & Trends Analysis Report Market by Products/ Services (Consumables and Services), by End-User (Pharmaceutical & Biotechnology Companies, Contract Research Organizations, and Academic & Research Institutes), and by Application (Cancer, Autoimmune Diseases, Hepatitis, Multiple Sclerosis, Hemophilia, Gastrointestinal Disorders, and Others) Forecast Period (2023-2030)” at https://www.omrglobal.com/industry-reports/pegylated-proteins-market
Pegunigalsidase alfa is a purposefully-designed, long-acting recombinant, PEGylated, cross-linked ?-galactosidase-A investigational product candidate. The FDA indicated in the BLA filing communication letter that the resubmitted BLA was considered a complete, class 2 response and set an action date of May 9, 2023, under the Prescription Drug User Fee Act (PDUFA).
Market Coverage
• The market number available for – 2022-2030
• Base year- 2022
• Forecast period- 2023-2030
• Segment Covered-
o By Products
o By Application
o By End-User
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
• Competitive Landscape- Thermo Fisher Scientific, Inc., Abcam plc, Enzon Pharmaceuticals, Inc., Merck KGaA, and Celares GmbH among others
Key questions addressed by the report
• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?
Global PEGylated Proteins Market Report Segment
By Products
By End-User
By Application
Global PEGylated Proteins Market Report Segment by Region
North America
• United States
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East & Africa
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/pegylated-proteins-market